Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma.

[1]  G. Atwal,et al.  Intratumoral dendritic cell–CD4^+ T helper cell niches enable CD8^+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma , 2023, Nature Medicine.

[2]  V. Sondak,et al.  Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. , 2023, The New England journal of medicine.

[3]  F. Tacke,et al.  Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art , 2023, Journal of hepatocellular carcinoma.

[4]  M. Merad,et al.  Neoadjuvant Immunotherapy for Hepatocellular Carcinoma , 2022, Journal of hepatocellular carcinoma.

[5]  Liyong Pu,et al.  Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial , 2022, Journal for ImmunoTherapy of Cancer.

[6]  Mingkai Chen,et al.  Declining disease burden of HCC in the United States, 1992–2017: A population‐based analysis , 2022, Hepatology.

[7]  V. Cristini,et al.  Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. , 2022, The lancet. Gastroenterology & hepatology.

[8]  Meredith R. Legg,et al.  Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. , 2022, The lancet. Gastroenterology & hepatology.

[9]  Donghee Kim,et al.  Current epidemiology in hepatocellular carcinoma , 2021, Expert review of gastroenterology & hepatology.

[10]  Ludmila V. Danilova,et al.  Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity , 2021, Nature Cancer.

[11]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[12]  Yi-yao Xu,et al.  Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma. , 2020, American journal of cancer research.

[13]  J. Marrero,et al.  Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference , 2020, Hepatology.

[14]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[15]  J. Taube,et al.  Neoadjuvant checkpoint blockade for cancer immunotherapy , 2020, Science.

[16]  T. Pawlik,et al.  Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma , 2019, World journal of gastroenterology.

[17]  G. Linette,et al.  A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.

[18]  Ralph Weissleder,et al.  Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.

[19]  A. Broeks,et al.  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma , 2018, Nature Medicine.

[20]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[21]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[22]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[23]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[24]  M. Smyth,et al.  Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease , 2016 .

[25]  A. Luciani,et al.  Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features , 2016, Hepatology.

[26]  M. Yano,et al.  Anatomical versus non‐anatomical resection for hepatocellular carcinoma , 2015, The British journal of surgery.

[27]  M. Schwartz,et al.  Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. , 2015, Annals of surgery.

[28]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[29]  J. Fallowfield,et al.  Liver fibrosis and repair: immune regulation of wound healing in a solid organ , 2014, Nature Reviews Immunology.

[30]  Lieping Chen,et al.  Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. , 2007, Blood.

[31]  G. Tiberio,et al.  Early and Late Recurrence After Liver Resection for Hepatocellular Carcinoma: Prognostic and Therapeutic Implications , 2006, Annals of surgery.

[32]  O. Finn.  Cancer immunology. , 2008, The New England journal of medicine.